TICKERNERD
Menu
JYNTJYNTHealthcare · Medical Care Facilities

JYNT Stock Forecast: The Joint Corp. (United States) Price Predictions for 2026-2027

Last close, 14 Oct 2026
$6.90
−1.08% on the day

The 4 Wall Street analysts covering The Joint Corp. (United States) hold a median 12-month price target of $9 — +30.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$98.6M
Ticker Nerd rank
91 / 100
Median analyst target
$9.00
Analysts covering
4
Revenue$15.2M+14.4% y/y
Operating income−$161K
Net income$653K
Free cash flow$1.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.2%
1M
−16.9%
YTD
−20.9%
1Y
−16.7%
From 52W high
−34.5%
From 52W low
0.0%
$7
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JYNT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores The Joint Corp. (United States) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
89
Quality
82
Accruals
78
Value
77
Growth
75
Size
75
Volatility
63
Revisions
59
Momentum
22

Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (22): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

JYNT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JYNT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$7$8$9$10$11$12Jan 26Apr 26Jul 26Oct 26JYNTHigh $12.00Median $9.00Low $9.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
1 Buy3 Hold0 Sell
Low $9.00Median $9.00High $12.00

The green dot is the last close — the median target sits +30.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 Aug 2025B. Riley SecuritiesMaintainsBuy$20 → $18
8 Aug 2025B. Riley SecuritiesMaintainsBuy—
9 May 2025Lake StreetMaintainsBuy—
8 Nov 2024Roth MKMMaintainsBuy—
6 May 2024B. Riley SecuritiesMaintainsBuy—
3 May 2024Roth MKMReiteratesBuy—
14 Sept 2023Roth MKMMaintainsBuy—
11 Aug 2023Maxim GroupDowngradeHold—
11 Aug 2023Roth MKMMaintainsBuy—
13 Mar 2023DA DavidsonUpgradeNeutral—
8 Aug 2022DA DavidsonMaintainsUnderperform—
5 Aug 2022B. Riley SecuritiesUpgradeBuy—
5 Aug 2022Maxim GroupUpgradeBuy—
10 May 2022DA DavidsonDowngradeUnderperform—
9 May 2022DA DavidsonDowngradeUnderperform—
6 May 2022Craig-HallumDowngradeHold—
25 Feb 2022DA DavidsonMaintainsBuy—
9 Aug 2021DA DavidsonMaintainsBuy—
6 Aug 2021Roth CapitalMaintainsBuy—
28 June 2021Roth CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JYNT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

JYNT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, The Joint Corp. (United States) returned −16.7% against +17.5% for the S&P 500, dividends included.

JYNT vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Jan 26Apr 26Jul 26Oct 26JYNTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

JYNT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−53.0%
Analysts raising
0
Analysts cutting
1
Fundamentals

The Joint Corp. (United States) (JYNT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
49.8×

Cheaper than 15% of US stocks

Price / sales
1.7×

Cheaper than 56% of US stocks

Price / book
6.0×

Cheaper than 16% of US stocks

EV / EBITDA
18.5×

Cheaper than 17% of US stocks

Growth & margins
Revenue growth (YoY)
14.4%

Higher than 61% of US stocks

Earnings growth (YoY)
599.4%

Higher than 96% of US stocks

Gross margin
83.7%

Higher than 93% of US stocks

Operating margin
3.2%

Higher than 51% of US stocks

Net margin
6.5%

Higher than 63% of US stocks

Returns & dividend
Return on equity
10.6%

Higher than 65% of US stocks

Return on assets
2.3%

Higher than 61% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

The Joint Corp. (United States) (JYNT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • The Joint Corp. (United States) has a market value of $98.6M and an enterprise value of $74.3M.

  • Revenue in the twelve months to 30 June 2026: $58.5M. The latest quarter grew 14.4% year on year.

  • Net income over the same four quarters: $3.8M, a 6.5% net margin.

  • Diluted earnings per share, trailing twelve months: $0.27.

  • Free cash flow in the twelve months to 30 June 2026: $4.2M.

  • The Joint Corp. (United States) spent $13.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 14.2M.

  • Trailing P/E: 49.8×; forward P/E: 10.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • The Joint Corp. (United States) employs 202 people — $290K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

JYNT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
JYNTThe Joint Corp. (United States)$98.6M
91
AIRSAirSculpt Technologies, Inc.$100.2M
52
PARKPark Dental Partners, Inc.$90.3M
14
WWWW International, Inc.$142.7M
66
BTMDbiote Corp.$40.2M
71
CCELCryo-Cell International, Inc.$33.5M
76
PIIIP3 Health Partners, Inc.$31.7M
67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own The Joint Corp. (United States) — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JYNT news & analysis

The Joint Chiropractic Expands Growth Opportunities Through Strategic Territory Reacquisition

PRNewsWire · 6 Oct 2026positive

The Joint Corp. announced it reacquired regional developer rights across Texas, including Dallas, Austin, San Antonio and Houston. The company said the agreement builds on 2026 territory reacquisitions representing more than 150 additional growth opportunities across multiple markets.

Why it matters — The reacquisition expands territory opportunities and supports The Joint’s stated transition to a pure-play franchisor.

The Joint Corp. (JYNT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of The Joint Corp.'s Q2 2026 earnings call. The item reports the availability of the call's full discussion and commentary.

Why it matters — The transcript gives JYNT watchers direct access to management's own account of the quarter's results and outlook.

Joint Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

The Joint Corp. reported second-quarter results that showed progress in its shift toward a capital-light, pure-play franchisor model. Management also said patient retention improved to its highest level in more than five years.

Why it matters — For JYNT watchers, the reported progress on its franchise-focused strategy and the improvement in patient retention point to the company's operational momentum in its core business.

The Joint Corp. (JYNT) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 7 Aug 2026negative

The Joint Corp. (JYNT) reported a Q2 loss of $0.01 per share, missing the Zacks Consensus Estimate of $0.11 per share. The loss narrowed compared to the $0.06 per share loss reported a year ago.

Why it matters — A JYNT watcher would note that the company's quarterly earnings fell short of analyst expectations, extending a pattern of losses.

The Joint Chiropractic Earns Entrepreneur Recognition as a Premier Multi-Unit Franchise Investment

PRNewsWire · 30 July 2026positive

The Joint Corp. has been named by Entrepreneur as one of its Top Brands for Multi-Unit Owners for 2026, recognizing the company as a premier growth opportunity for experienced multi-unit and multi-brand investors.

Why it matters — The recognition signals to JYNT watchers that the company's franchise model continues to gain credibility and traction among experienced investors in the healthcare franchise space.

FAQ

Frequently asked questions about JYNT stock

What is the JYNT stock price forecast for 2026-2027?

The 4 Wall Street analysts covering The Joint Corp. (United States) have a median 12-month price target of $9, with estimates ranging from $9 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JYNT stock a buy right now?

Of the 4 analysts covering The Joint Corp. (United States), 1 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Joint Corp. (United States) 91 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JYNT?

As at 14 Oct 2026, The Joint Corp. (United States) ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).

Will JYNT stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +30.4% from the last close, and Ticker Nerd's factor model ranks The Joint Corp. (United States) 91 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JYNT stock forecast for 2030?

No analyst covering The Joint Corp. (United States) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JYNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $12 over the next 12 months.

How has JYNT stock performed over the past year?

The Joint Corp. (United States) returned -16.7% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does The Joint Corp. (United States) do?

The Joint Corp. is a healthcare services company that operates and franchises chiropractic clinics across the United States through The Joint Chiropractic brand.

What is the latest news on JYNT?

The most recent item we track (PRNewsWire, 6 Oct 2026): "The Joint Chiropractic Expands Growth Opportunities Through Strategic Territory Reacquisition". The Joint Corp. announced it reacquired regional developer rights across Texas, including Dallas, Austin, San Antonio and Houston. The company said the agreement builds on 2026 territory reacquisitions representing more than 150 additional growth opportunities across multiple markets.

Company

About The Joint Corp. (United States).

The Joint Corp. is a healthcare services company that operates and franchises chiropractic clinics across the United States through The Joint Chiropractic brand. The company focuses on providing walk-in, appointment-free care for patients seeking relief from musculoskeletal pain and ongoing wellness support. Its clinics use a private-pay, non-insurance model that is designed to make chiropractic services more accessible and convenient for routine visits. The Joint Corp. serves consumers through a network that includes company-operated locations and franchised clinics, with services supported by membership-based wellness plans and standardized clinic operations. Headquartered in Scottsdale, Arizona, The Joint Corp. plays a significant role in the retail chiropractic market by combining local clinic access with a scalable franchising model.

CEO Mr. Sanjiv Razdan · 202 employees · United States · https://www.thejoint.com